Bacopa monnieri significantly improved memory span as well as verbal and visual memory in children and adolescents. Two studies reported improvements in hyperactivity and attention in children diagnosed with ADHD. Significant outcomes demonstrated small to medium effect sizes (mean d = 0.42). Bacopa monnieri was well tolerated with only 2.3% of all participants reporting mild side-effects. Standardized trial designs in clinical paediatric populations are essential to ensure the outcomes reported are reliable and valid.